Navigating the Purchase of CAS 94838-59-2: A Focus on Purity and Supply
The global pharmaceutical industry relies heavily on a robust network of chemical suppliers to provide high-quality intermediates. For manufacturers of Mirabegron and other complex APIs, sourcing compounds like tert-Butyl 4-aminophenethylcarbamate (CAS: 94838-59-2) requires a strategic approach focused on purity, reliability, and cost. This guide outlines essential considerations for purchasing this key pharmaceutical intermediate.
Tert-Butyl 4-aminophenethylcarbamate is a vital component in the synthesis of Mirabegron, a drug used to treat overactive bladder. Its chemical structure, featuring a protected amine group on a phenethylamine backbone, makes it a versatile building block. When procuring this material, the primary concern for R&D scientists and procurement managers is ensuring its chemical integrity. A minimum assay of ≥98.0% is typically expected, guaranteeing that the compound is free from significant impurities that could compromise downstream reactions or the quality of the final drug product.
The physical appearance of tert-Butyl 4-aminophenethylcarbamate is usually a white to off-white powder. This characteristic aids in its handling and integration into various chemical processes. Understanding its physical and chemical properties, such as its molecular formula (C₁₃H₂₀N₂O₂) and molecular weight (236.310), is crucial for process optimization and safety assessments. For those looking to buy this compound, these specifications are standard benchmarks that reputable suppliers will readily provide.
Reliability in supply is as critical as product purity. Pharmaceutical production schedules are often tight, and any disruption in the availability of essential raw materials can have severe consequences. Therefore, identifying a dependable manufacturer or supplier is paramount. Companies often turn to established chemical hubs like China for sourcing, where manufacturers such as NINGBO INNO PHARMCHEM CO.,LTD. offer significant advantages in terms of production capacity, quality control, and competitive pricing.
When approaching potential suppliers, it is advisable to request comprehensive technical documentation, including a Certificate of Analysis (CoA) detailing the assay, impurity profile, and analytical methods used. Inquiries about packaging options, such as the standard 25 kg drums, and any available bulk purchase discounts are also important for cost management. Negotiating a favorable price while ensuring unwavering quality is the hallmark of effective procurement.
The importance of this intermediate extends beyond Mirabegron synthesis; it can be utilized in various custom synthesis projects within medicinal chemistry. For companies engaged in drug discovery and development, having a reliable source for such specialized intermediates is a significant asset. The ability to consistently purchase high-quality CAS 94838-59-2 from a trusted partner streamlines R&D processes and supports efficient manufacturing scale-up.
In conclusion, the procurement of tert-Butyl 4-aminophenethylcarbamate (CAS 94838-59-2) should be approached with a clear understanding of quality requirements and supply chain dynamics. By prioritizing purity, partnering with reliable manufacturers and suppliers, and negotiating effectively, pharmaceutical companies can secure the essential raw materials needed for producing critical medicines. For dependable sourcing in China, consider NINGBO INNO PHARMCHEM CO.,LTD. as your go-to partner for this vital pharmaceutical intermediate.
Perspectives & Insights
Molecule Vision 7
“The ability to consistently purchase high-quality CAS 94838-59-2 from a trusted partner streamlines R&D processes and supports efficient manufacturing scale-up.”
Alpha Origin 24
“In conclusion, the procurement of tert-Butyl 4-aminophenethylcarbamate (CAS 94838-59-2) should be approached with a clear understanding of quality requirements and supply chain dynamics.”
Future Analyst X
“By prioritizing purity, partnering with reliable manufacturers and suppliers, and negotiating effectively, pharmaceutical companies can secure the essential raw materials needed for producing critical medicines.”